Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Kamb

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Nature Reviews. Drug Discovery|February 3, 2005
What's wrong with our cancer models?Alexander Kamb
Nature|March 14, 2003
Universities could gain from backing biotechAlexander Kamb
Chemical Research in Toxicology|June 3, 2011
Next-generation sequencing and its potential impactAlexander Kamb
Current Opinion in Pharmacology|June 15, 2010
At a crossroads in oncologyAlexander Kamb
Molecular Biology of the Cell|June 17, 2003
Consequences of nonadaptive alterations in cancerAlexander Kamb
Journal of Theoretical Biology|June 20, 2003
Mutation load, functional overlap, and synthetic lethality in the evolution and treatment of cancerAlexander Kamb
Current Gene Therapy|October 8, 2003
Non-traditional drug targets: high risk, high rewardTanya Sandrock, Alexander Kamb
F1000Research|March 22, 2016
Publishing confirming and non-confirming dataBruce Alberts, Alexander Kamb
Frontiers in Immunology|April 1, 2025
Editorial: The next stage of immune cell design: selective targeting of multi-antigen profilesAlexander Kamb, Jackson G Egen
F1000Research|January 14, 2021
Cancer T-cell therapy: building the foundation for a cureAlexander Kamb, William Y Go
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Nature Reviews. Drug Discovery|February 3, 2005
What's wrong with our cancer models?Alexander Kamb
Nature|March 14, 2003
Universities could gain from backing biotechAlexander Kamb
Chemical Research in Toxicology|June 3, 2011
Next-generation sequencing and its potential impactAlexander Kamb
Current Opinion in Pharmacology|June 15, 2010
At a crossroads in oncologyAlexander Kamb
Molecular Biology of the Cell|June 17, 2003
Consequences of nonadaptive alterations in cancerAlexander Kamb
Journal of Theoretical Biology|June 20, 2003
Mutation load, functional overlap, and synthetic lethality in the evolution and treatment of cancerAlexander Kamb
Current Gene Therapy|October 8, 2003
Non-traditional drug targets: high risk, high rewardTanya Sandrock, Alexander Kamb
F1000Research|March 22, 2016
Publishing confirming and non-confirming dataBruce Alberts, Alexander Kamb
Frontiers in Immunology|April 1, 2025
Editorial: The next stage of immune cell design: selective targeting of multi-antigen profilesAlexander Kamb, Jackson G Egen
F1000Research|January 14, 2021
Cancer T-cell therapy: building the foundation for a cureAlexander Kamb, William Y Go
Pageof 5